UPDATE: In mid-2025, Syncona proposed a managed wind-down but a few months later shifted its plans to return £250m to shareholders instead, funded by sales proceeds from its more mature investments, and limiting new investments while this process takes place.

Syncona (SYNC) was launched in 2012 as BACIT (Battle Against Cancer Investment Trust). It initially invested in a range of investment funds but in 2016, it acquired a life sciences investment business set up by The Wellcome Trust and renamed itself Syncona. Wellcome Trust sold a quarter of its stake in 2019 but still owns 186m shares giv...